R&G PharmaStudies Co. Ltd. A (SHE:301333) — Market Cap & Net Worth
Market Cap & Net Worth: R&G PharmaStudies Co. Ltd. A (301333)
R&G PharmaStudies Co. Ltd. A (SHE:301333) has a market capitalization of $909.45 Million (CN¥6.22 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #9382 globally and #2366 in its home market, demonstrating a 7.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying R&G PharmaStudies Co. Ltd. A's stock price CN¥64.35 by its total outstanding shares 96581256 (96.58 Million). Also see 301333 total assets for a full breakdown of the balance sheet.
R&G PharmaStudies Co. Ltd. A Market Cap History: 2022 to 2026
R&G PharmaStudies Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows growth from $719.71 Million to $909.45 Million (3.57% CAGR). Also see 301333 cash flow conversion for how efficiently the company converts equity into cash flow.
R&G PharmaStudies Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how R&G PharmaStudies Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check R&G PharmaStudies Co. Ltd. A stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.99x
R&G PharmaStudies Co. Ltd. A's market cap is 0.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.15x
R&G PharmaStudies Co. Ltd. A's market cap is 6.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $719.71 Million | $637.52 Million | $113.45 Million | 1.13x | 6.34x |
| 2023 | $906.09 Million | $721.37 Million | $162.53 Million | 1.26x | 5.57x |
| 2024 | $706.50 Million | $744.00 Million | $140.22 Million | 0.95x | 5.04x |
| 2025 | $841.61 Million | $851.01 Million | $136.90 Million | 0.99x | 6.15x |
Competitor Companies of 301333 by Market Capitalization
Companies near R&G PharmaStudies Co. Ltd. A in the global market cap rankings as of September 19, 2026. Review 301333 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to R&G PharmaStudies Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
R&G PharmaStudies Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, R&G PharmaStudies Co. Ltd. A's market cap moved from $719.71 Million to $ 909.45 Million, with a yearly change of 3.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥909.45 Million | +8.06% |
| 2025 | CN¥841.61 Million | +19.12% |
| 2024 | CN¥706.50 Million | -22.03% |
| 2023 | CN¥906.09 Million | +25.90% |
| 2022 | CN¥719.71 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of R&G PharmaStudies Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $909.45 Million USD |
| MoneyControl | $909.45 Million USD |
| MarketWatch | $909.45 Million USD |
| marketcap.company | $909.45 Million USD |
| Reuters | $909.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more